A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients

Cancer Journal (United States)

Volumn 20, Issue 1, 2014, Pages 8-14

  Escalante, Carmen P ^a   Meyers, Christina ^a   Reuben, James M ^a   Wang, Xuemei ^a   Qiao, Wei ^a   Manzullo, Ellen ^a   Alvarez, Ricardo H ^a   Morrow, Phuong Khanh ^b   Gonzalez Angulo, Ana M ^a   Wang, Xin Shelley ^a   Mendoza, Tito ^a   Liu, Wenli ^a   Holmes, Holly ^a   Hwang, Jessica ^a   Pisters, Katherine ^a   Overman, Michael ^a   Cleeland, Charles ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMGEN INC   (United States)

Author keywords

cancer; Cancer related fatigue; methylphenidate; stimulant; sustained release methylphenidate

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6 RECEPTOR; METHYLPHENIDATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; CENTRAL STIMULANT AGENT; DELAYED RELEASE FORMULATION;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY DISORDER; BRIEF FATIGUE INVENTORY; CANCER FATIGUE; CANCER PATIENT; CLINICAL ARTICLE; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DIGIT SYMBOL TEST; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; EPISTAXIS; FACE RASH; FEMALE; HEART PALPITATION; HOPKINS VERBAL LEARNING TEST; HUMAN; INSOMNIA; LEARNING; LOW DRUG DOSE; MALE; MEMORY; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEUROPATHY; PATIENT PREFERENCE; PERCEPTION; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SINUS CONGESTION; SORE THROAT; SUSTAINED DRUG RELEASE; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WECHSLER INTELLIGENCE SCALE; WORK; XEROSTOMIA; COMPLICATION; DELAYED RELEASE FORMULATION; FATIGUE; NEOPLASMS;

ADULT; AGED; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; NEOPLASMS; PLACEBOS;

EID: 84893543233     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000018     Document Type: Conference Paper

References (23)

1. Curt GA, BreitbartW, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000;5:353-360.
2. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997;34:4-12.
3. Stasi R, Abriani L, Beccaglia P, et al. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer. 2003;98:1786-1801.
4. Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist. 2003;8(suppl 1):5-9.
5. Wang XS, Giralt SA, Mendoza TR, et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:1319-1328.
6. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-655.
7. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-1196.
8. Wechsler D. Wechsler Adult Intelligence Scale (Rev. ed.). New York: Psychological Corporation; 1981.
9. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalents forms. Clin Neuropsychol. 1991; 5:125-142.
10. Benton A, Hamsher K, Sivan A. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates: Inc; 1989.
11. Lezak M, Howieson D, Loring D, et al. Neurophysiological assessment. J Clin Psychol. 1995;50:596-600.
12. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
13. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56:893-897.
14. Anderson KO, Getto CJ,Mendoza TR, et al. Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and communitydwelling adults. J Pain Symptom Manage. 2003;25:307-318.
15. Cella DF, Jacobsen PB, Orav EJ, et al. A brief POMS measure of distress for cancer patients. J Chronic Dis. 1987;40:939-942.
16. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89:1634-1646.
17. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
18. Moraska AR, Sood A, Dakhil SR, et al. Phase III, randomized, doubleblind, placebo-controlled study of long-acting methylphenidate for cancerrelated fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28:3673-3679.
19. Lower EE, Fleishman S, Cooper A, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009;38:650-662.
20. Roth AJ, Nelson C, Rosenfeld B, et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer. 2010;116:5102-5110.
21. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005; 30:100-107.
22. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788-793.
23. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 2001;92:1684-1688.